[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100648090":3},{"organization":4,"armGroups":7,"interventions":36,"overallOfficials":42,"centralContacts":51,"locations":57,"responsibleParty":71,"collaborators":42,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":42,"eligibilityCriteria":79,"healthyVolunteers":80,"sex":81,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":42,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":42,"overallStatus":93,"whyStopped":42,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Addpharma Inc.","INDUSTRY",[8,16,20,24,28,32],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm A(Vonoprazan, Fexuprazan, Vonoprazan)","EXPERIMENTAL","Participants receive AD-234 - AD-2341-AD-2342",[13,14,15],"Drug: AD-234","Drug: AD-2341","Drug: AD-2342",{"label":17,"type":10,"description":18,"interventionNames":19},"Arm B(Vonoprazan, Vonoprazan, Fexuprazan)","Participants receive AD-234 - AD-2342- AD-2341",[13,14,15],{"label":21,"type":10,"description":22,"interventionNames":23},"Arm C(Fexuprazan, Vonoprazan, Vonoprazan)","Participants receive AD-2341-AD-234-AD-2342",[13,14,15],{"label":25,"type":10,"description":26,"interventionNames":27},"Arm D(Fexuprazan, Vonoprazan, Vonoprazan)","Participants receive AD-2341-AD-2342-AD-234",[13,14,15],{"label":29,"type":10,"description":30,"interventionNames":31},"Arm E(Vonoprazan, Vonoprazan, Fexuprazan)","Participants receive AD-2342 -AD-234-AD-2341",[13,14,15],{"label":33,"type":10,"description":34,"interventionNames":35},"Arm F(Vonoprazan, Fexuprazan, Vonoprazan)","Participants receive AD-2342-AD-2341-AD-234",[13,14,15],[37,43,47],{"type":38,"name":39,"description":40,"armGroupLabels":41,"otherNames":42},"DRUG","AD-234","AD-234 tablet administered orally",[9,17,21,25,29,33],null,{"type":38,"name":44,"description":45,"armGroupLabels":46,"otherNames":42},"AD-2341","AD-2341 tablet administered orally",[9,17,21,25,29,33],{"type":38,"name":48,"description":49,"armGroupLabels":50,"otherNames":42},"AD-2342","AD-2342 tablet administered orally",[9,17,21,25,29,33],[52],{"name":53,"role":54,"phone":55,"phoneExt":42,"email":56},"JaeHun Jung","CONTACT","+82-31-891-5683","jhjung@addpharma.co.kr",[58],{"facility":59,"status":42,"city":60,"state":42,"zip":42,"country":61,"countryCode":42,"cosmosGeoPoint":62,"geoPoint":67,"contacts":68},"Seoul National University Hospital, Seoul,","Seoul","South Korea",{"type":63,"coordinates":64},"Point",[65,66],126.9784,37.566,{"lat":66,"lon":65},[69],{"name":70,"role":54,"phone":42,"phoneExt":42,"email":42},"Seunghwan Lee",{"type":72,"investigatorFullName":42,"investigatorTitle":42,"investigatorAffiliation":42,"oldNameTitle":42,"oldOrganization":42},"SPONSOR","100648090","phase-1-a-study-of-compare-the-pharmacokinetic-pharmacodynamic-and-safetytolerability-characteristics-following-multiple-oral-administration-of-ad-234-ad-2341-and-ad-2342-in-healthy-adults-100648090",false,"NCT07717775","A Study of Compare the Pharmacokinetic, Pharmacodynamic and Safety\u002FTolerability Characteristics Following Multiple Oral Administration of AD-234, AD-2341, and AD-2342 in Healthy Adults","A Randomized, Open-label, 6-sequence, 3-period Crossover Clinical Trial to Compare the Pharmacokinetic, Pharmacodynamic and Safety\u002FTolerability Characteristics Following Multiple Oral Administration of AD-234, AD-2341, and AD-2342 in Healthy Adult Volunteers.","Inclusion Criteria:\n\n* Healthy adult volunteers aged 19 to 50 years, inclusive, at the time of screening\n\n  * Body weight between 50.0 kg and 90.0 kg, inclusive, and body mass index (BMI) between 18.5 kg\u002Fm\\^2 and 29.9 kg\u002Fm\\^2, inclusive, at the time of screening (BMI = weight \\[kg\\] \u002F height \\[m\\]\\^2)\n  * For female participants: not pregnant, not breastfeeding, or surgically sterile (e.g., bilateral tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy)\n\nExclusion Criteria:\n\n* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration Other exclusions applied",true,"ALL","19 Years","50 Years",{"count":85,"type":86},30,"ESTIMATED","INTERVENTIONAL",[89],"PHASE1","Primary endpoint of this study is to evaluate the pharmacokinetic and pharmacodynamic characteristics of AD-234, AD-2341, AD-2342 in healthy subjects.",[92],"Gastritis","NOT_YET_RECRUITING","2026-07-24",{"date":96,"type":97},"2026-07-27","ACTUAL",{"date":99,"type":86},"2026-08",{"date":101,"type":86},"2026-11",{"name":5,"class":6},1]